Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) was upgraded by equities researchers at Wall Street Zen from a "strong sell" rating to a "hold" rating in a research report issued on Thursday.
Separately, Guggenheim started coverage on shares of Eledon Pharmaceuticals in a research report on Tuesday, January 28th. They issued a "buy" rating and a $9.00 price objective for the company.
Check Out Our Latest Report on ELDN
Eledon Pharmaceuticals Trading Up 1.0%
NASDAQ:ELDN traded up $0.03 during trading hours on Thursday, hitting $3.05. The stock had a trading volume of 175,430 shares, compared to its average volume of 273,037. Eledon Pharmaceuticals has a 1-year low of $2.30 and a 1-year high of $5.54. The business has a 50 day simple moving average of $3.12 and a two-hundred day simple moving average of $3.88. The company has a market cap of $182.64 million, a PE ratio of -1.52 and a beta of 0.08.
Eledon Pharmaceuticals (NASDAQ:ELDN - Get Free Report) last issued its quarterly earnings data on Wednesday, May 14th. The company reported ($0.08) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.20. Research analysts expect that Eledon Pharmaceuticals will post -0.81 EPS for the current fiscal year.
Hedge Funds Weigh In On Eledon Pharmaceuticals
Several institutional investors and hedge funds have recently made changes to their positions in the business. RA Capital Management L.P. purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at approximately $14,693,000. Sphera Funds Management LTD. boosted its stake in shares of Eledon Pharmaceuticals by 96.7% during the 4th quarter. Sphera Funds Management LTD. now owns 2,551,619 shares of the company's stock valued at $10,513,000 after buying an additional 1,254,298 shares during the last quarter. First Light Asset Management LLC purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at approximately $9,595,000. Blue Owl Capital Holdings LP purchased a new position in shares of Eledon Pharmaceuticals during the 4th quarter valued at approximately $8,075,000. Finally, Woodline Partners LP boosted its stake in shares of Eledon Pharmaceuticals by 98.3% during the 4th quarter. Woodline Partners LP now owns 1,671,822 shares of the company's stock valued at $6,888,000 after buying an additional 828,930 shares during the last quarter. 56.77% of the stock is currently owned by hedge funds and other institutional investors.
About Eledon Pharmaceuticals
(
Get Free Report)
Eledon Pharmaceuticals, Inc operates as a clinical stage biotechnology company. The company uses its immunology expertise in targeting the CD40 Ligand (CD40L, also called CD154) pathway to develop therapies to protect transplanted organs and prevent rejection, and to treat amyotrophic lateral sclerosis (ALS).
Further Reading
Before you consider Eledon Pharmaceuticals, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eledon Pharmaceuticals wasn't on the list.
While Eledon Pharmaceuticals currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat's analysts have just released their top five short plays for June 2025. Learn which stocks have the most short interest and how to trade them. Enter your email address to see which companies made the list.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
